Roche has licensed Amunix Pharmaceuticals’ XTEN platform to discover and develop non-oncology therapeutics against certain undisclosed targets.
The agreement builds on Amunix’s previous technology assessment with Roche focused on using XTEN, a proprietary unstructured polypeptide, to extend drug half-life.
Amunix will receive a $40 million upfront payment from Roche. Amunix may also receive up to $1.5 billion in payments from Roche associated with the achievement of certain developmental and sales milestones, plus royalties on sales of commercialized products.
Angie You, CEO of Amunix, said: “As we continue to pivot from purely a technology licensing company to a cancer drug discovery and development organisation, we look forward to Roche and other external collaborators continuing to utilise our XTEN technology for a spectrum of indications while we focus our internal efforts on repurposing this technology to build a pro-drug platform and advance an oncology pipeline.”